Hughes TP - Search Results

1

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR. Mullighan CG, et al. Among authors: hughes tp. Nature. 2008 May 1;453(7191):110-4. doi: 10.1038/nature06866. Epub 2008 Apr 13. Nature. 2008. PMID: 18408710

2

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB, Hughes T. White D, et al. Blood. 2005 Oct 1;106(7):2520-6. doi: 10.1182/blood-2005-03-1103. Epub 2005 Jun 14. Blood. 2005. PMID: 15956284 Free article.

3

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.

White D, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF, Lynch K, To LB, Hughes T. White D, et al. J Clin Oncol. 2007 Oct 1;25(28):4445-51. doi: 10.1200/JCO.2006.09.9499. J Clin Oncol. 2007. PMID: 17906206

4

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells.

Hiwase DK, White DL, Saunders VA, Kumar S, Melo JV, Hughes TP. Hiwase DK, et al. Among authors: hughes tp. Leukemia. 2009 Jun;23(6):1205-6. doi: 10.1038/leu.2009.45. Epub 2009 Mar 5. Leukemia. 2009. PMID: 19262594 No abstract available.

5

Lin28 promotes transformation and is associated with advanced human malignancies.

Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ. Viswanathan SR, et al. Among authors: hughes tp. Nat Genet. 2009 Jul;41(7):843-8. doi: 10.1038/ng.392. Epub 2009 May 31. Nat Genet. 2009. PMID: 19483683 Free PMC article.

6

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.

Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, Guthridge MA, Lopez AF, D'Andrea RJ, To LB, Melo JV, Kumar S, Hughes TP. Hiwase DK, et al. Among authors: hughes tp. Leukemia. 2010 Apr;24(4):771-8. doi: 10.1038/leu.2009.299. Epub 2010 Feb 4. Leukemia. 2010. PMID: 20130598

7

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.

Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL. Engler JR, et al. Among authors: hughes tp. Leukemia. 2010 Apr;24(4):765-70. doi: 10.1038/leu.2010.16. Epub 2010 Feb 11. Leukemia. 2010. PMID: 20147974

8

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells.

Eadie L, Hughes TP, White DL. Eadie L, et al. Among authors: hughes tp. Leukemia. 2010 Apr;24(4):855-7. doi: 10.1038/leu.2010.7. Epub 2010 Feb 11. Leukemia. 2010. PMID: 20147980 No abstract available.

9

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.

White DL, Saunders VA, Dang P, Engler J, Hughes TP. White DL, et al. Among authors: hughes tp. Leukemia. 2010 Nov;24(11):1962-5. doi: 10.1038/leu.2010.188. Epub 2010 Sep 2. Leukemia. 2010. PMID: 20811406 No abstract available.

10

OCT-1 as a determinant of response to antileukemic treatment.

Engler JR, Hughes TP, White DL. Engler JR, et al. Among authors: hughes tp. Clin Pharmacol Ther. 2011 Apr;89(4):608-11. doi: 10.1038/clpt.2011.12. Epub 2011 Feb 23. Clin Pharmacol Ther. 2011. PMID: 21346750 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

368 results

Search Page